Olaparib Impurity Standards

Olaparib, an antineoplastic drug treating advanced ovarian cancer, is a potent inhibitor of both PARP-1 and PARP-2.  Olaparib acts against  patients with germline BRCA1/2-mutations who have HER2-negative locally advanced or metastatic ovarian, breast and prostate cancers.

Various Olaparib related compounds or reference standards, listed on this page are needed in pharmaceutical research at the time to product development, ANDA filing or during production to study quality, stability, and genotoxicity study of Olaparib related products. 

1460272-52-9	Olaparib Carbonyl Impurity
1956340-97-8	Olaparib Impurity 11
2250242-62-5	Olaparib Impurity 14
763111-47-3	4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one
2415448-60-9	Benzamide, 5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluoro-N,N-dimethyl-
420846-72-6	3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
2514757-44-7	1(2H)-Phthalazinone, 4-[[4-fluoro-3-[[4-(4-hydroxy-1-oxobutyl)-1-piperazinyl]carbonyl]phenyl]methyl]-
1021298-68-9	2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)Methyl)benzonitrile